/PRNewswire/ Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide.
/PRNewswire/ Adela, Inc. presented data today demonstrating the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse.
/PRNewswire/ Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the.